Close Menu

NEW YORK — Investment bank William Blair on Tuesday initiated coverage of point-of-care diagnostic firm Lucira Health with an Outperform rating.

In a research note, William Blair analyst Brian Weinstein wrote that Lucira has developed a simple, handheld, single-use MDx test powered by batteries and that use-cases for the product are "large and still evolving."

In particular, the investment bank sees potential for expanded use of Lucira's test in the over-the-counter markets, where the company may become one of the first to receive Emergency Use Authorization.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.